
    
      The objective of this study was to evaluate the efficacy and safety of AndroGel (testosterone
      gel) 1% following administration in community dwelling men with hypogonadism. The percent
      change from baseline to Month 6 in aging male symptom (AMS) assessment was the primary
      endpoint. Secondary endpoints were changes from baseline to Month 6 in International Index of
      Erectile Dysfunction (IIEF), Multidimensional Fatigue Inventory (MFI), and body mass index
      (BMI) assessments.
    
  